AHA 2024 – Tirzepatide lowers the risk of worsening heart failure and CVD death for obese adults
Researchers from the SUMMIT trial have reported that treatment with tirzepatide has reduced the risk of worsening heart failure and cardiovascular disease-related death for obese adults. The findings… read more.